Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 143 The United Laboratories International Holdings Limited Annual Report 2025 37. FINANCIAL INSTRUMENTS (Continued) Financial risk management objectives and policies (Continued) Credit risk and impairment assessment (Continued) The following table shows the movement in ECL that has been recognised for consideration receivables, banker’s acceptance bills receivables and other receivables. Lifetime ECL (credit- 12m ECL impaired) Total RMB’000 RMB’000 RMB’000 At 1 January 2024 6,137 339,574 345,711 Changes due to bills and other receivables recognised at 1 January 2024: – Impairment losses reversed (6,137) – (6,137) Newly originated bills and other receivables 11,763 – 11,763 At 31 December 2024 11,763 339,574 351,337 Changes due to bills and other receivables recognised at 1 January 2025: – Impairment losses reversed (11,763) – (11,763) Newly originated bills and other receivables 13,345 – 13,345 At 31 December 2025 13,345 339,574 352,919